Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMF4YGC)

• Drug Name: P-coumaric acid derivative 6 Drug Info
• Synonyms: PMID26815044-Compound-63

Indication

Disease Entry	ICD 11	Status	REF
Albinism	EC23.2	Patented	[1]
Ephelides	ED61.0	Patented	[1]
Melasma	ED60.1	Patented	[1]
Menkes disease	5C64.0	Patented	[1]
Senile lentigines	ED61.0	Patented	[1]

• Cross-matching ID:
  PubChem CID: 5372945
  ChEBI ID: CHEBI:65665
  CAS Number: CAS 36417-86-4
  TTD Drug ID: DMF4YGC

Molecule-Related Drug Atlas

Drug(s) Targeting Tyrosinase (TYR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[3]
Monobenzone	DMVJS2K	Vitiligo	ED63.0	Approved	[3]
Multi-epitope peptide melanoma vaccine	DMZPEHY	Melanoma	2C30	Phase 3	[4]
Melanoma vaccine	DMQEC6Z	Melanoma	2C30	Phase 3	[5]
Polynoma-1	DM3QDA6	Melanoma	2C30	Phase 2	[6]
MKC-1106-MT	DMXKOW6	Melanoma	2C30	Phase 2	[7]
Multi-epitope tyrosinase/gp100 vaccine	DMN68ZL	Melanoma	2C30	Phase 2	[8]
PMID29130358-Compound-Figure11(3)	DMSME2B	N. A.	N. A.	Patented	[9]
Benzothiazole analog 1	DMHXFCQ	Albinism	EC23.2	Patented	[1]
Monoamine derivative 2	DMAZ6DI	Albinism	EC23.2	Patented	[1]

Drug(s) Affected By Epidermal growth factor receptor (EGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BIBW 2992	DMTKD7Q	Non-small-cell lung cancer	2C25.Y	Approved	[10]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[11]
Erlotinib	DMCMBHA	Adrenal gland neoplasm		Approved	[12]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[13]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[14]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[15]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[16]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[17]
Selenium	DM25CGV	N. A.	N. A.	Approved	[18]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tyrosinase (TYR)	TTULVH8	TYRO_HUMAN	Inhibitor	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Epidermal growth factor receptor (EGFR)	OTAPLO1S	EGFR_HUMAN	Gene/Protein Processing	[2]

References

• [1] Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.
• [2] Synthesis and characterization of N-coumaroyltyramine as a potent phytochemical which arrests human transformed cells via inhibiting protein tyrosine kinases. Biochem Biophys Res Commun. 2002 Apr 12;292(4):1104-10. doi: 10.1006/bbrc.2002.6752.
• [3] Identification of an Alkylhydroquinone from Rhus succedanea as an Inhibitor of Tyrosinase and Melanogenesis. J Agric Food Chem. 2009 Mar 25;57(6):2200-5.
• [4] Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in-adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. Correction in: volume 35 on page 650.
• [5] National Cancer Institute Drug Dictionary (drug id 685201).
• [6] An immuno-oncology company developing a novel polyvalent antigen therapy for the treatment of melanoma. Polynoma. 2015.
• [7] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [8] ClinicalTrials.gov (NCT00003362) Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma. U.S. National Institutes of Health.
• [9] Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
• [10] Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors. J Med Chem. 2011 Mar 10;54(5):1347-55. doi: 10.1021/jm101396q. Epub 2011 Feb 15.
• [11] Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 2006 Jun 1;66(11):5542-8. doi: 10.1158/0008-5472.CAN-05-4620.
• [12] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004 May 20;350(21):2129-39. doi: 10.1056/NEJMoa040938. Epub 2004 Apr 29.
• [13] The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005 Jan 1;65(1):18-25.
• [14] A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer. Mol Cancer Ther. 2010 Feb;9(2):311-8. doi: 10.1158/1535-7163.MCT-09-0693. Epub 2010 Jan 26.
• [15] Prediction of chemosensitivity using multigene analysis in head and neck squamous cell carcinoma. Oncology. 2007;73(1-2):104-11. doi: 10.1159/000120998. Epub 2008 Mar 13.
• [16] Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology. 2014 Aug 1;322:78-88. doi: 10.1016/j.tox.2014.05.007. Epub 2014 May 24.
• [17] Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
• [18] Inhibition of invasion and induction of apoptosis by selenium in human malignant brain tumour cells in vitro. Int J Oncol. 2007 May;30(5):1263-71.
• [19] Ligand-dependent activation of the epidermal growth factor receptor by secondary bile acids in polarizing colon cancer cells. Surgery. 2005 Sep;138(3):415-21. doi: 10.1016/j.surg.2005.06.030.